Internally administered therapeutic agents for diseases in central and peripheral nervous system comprising mesenchymal cells as an active ingredient
AssigneesRenomedix Institute, Inc., Aska Pharmaceutical Co., Ltd., Mitsui Sumitomo Insurance Co., Ltd., Hitachi, Ltd.
InventorsOsamu Honmou, Hirofumi Hamada
Life of this patent
Estimating the term…
Abstract
Intravenous administration of bone marrow cells collected from rat bone marrow to a rat cerebral infarction model was found to be effective in treating cerebral infarction. Human and murine bone marrow stem cells showed similar effects. Mesenchymal cells such as bone marrow cells, cord blood cells, or peripheral blood cells can be used as agents for in vivo administration against cranial nerve diseases.
Claims13
A cranial nerve disease therapeutic agent for in vivo administration, comprising a mesenchymal cell as an active ingredient.
An agent for in vivo administration, exhibiting neuroprotection and comprising a mesenchymal cell as an active ingredient.
An agent for in vivo administration, exhibiting cranial nerve regeneration and comprising a mesenchymal cell as an active ingredient.
Dependencies are inferred from the claim text.